Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Details : Undisclosed
Product Name : Zevalin
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 10, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 24, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Zevalin
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 13, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable